| Autor: |
Tan, Shirley Siang Ning, Fong, Alan Yean Yip, Mejin, Melissa, Gerunsin, Jerry, Kong, Khai Liy, Chin, Felicia Yien Yin, Tiong, Lee Len, Lim, Melissa Siaw Han, Said, Asri, Khiew, Ning Zan, Voon, Chi Yen, Mohd Amin, Nor Hanim, Cham, Yee Ling, Koh, Keng Tat, Oon, Yen Yee, Ong, Tiong Kiam |
| Zdroj: |
Pharmacogenomics; August 2017, Vol. 18 Issue: 13 p1225-1239, 15p |
| Abstrakt: |
Background:Patients undergoing elective percutaneous coronary intervention (PCI) with drug-eluting stents (DES) who have impaired clopidogrel response, have a higher risk of subsequent major adverse cardiovascular events (MACE). Aim of the study:To establish the relationship between CYP2C19genotype, clopidogrel responsiveness and 1–year MACE. Materials & methods:Aspirin/clopidogrel responses were assessed with Multiplate Analyzer and CYP2C192allele by SpartanRx. Results:A total of 42.0 carried ≥1 CYP2C192allele. Prevalences of aspirin and clopidogrel high on-treatment platelet reactivity (HPR; local cutoffs: 300 AUmin for aspirin and 600 AUmin for clopidogrel) were 11.5 and 19.8 respectively. In multivariate analysis, clopidogrel HPR was found to be an independent predictor for 1–year MACE (adj HR: 3.48, p 0.022 ). Conclusion:Having clopidogrel HPR could be a potentially modifiable risk factor guided by phenotyping. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
